Keros Therapeutics, Inc. (NASDAQ:KROS – Get Free Report) Director Carl L. Gordon sold 250,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $44.01, for a total transaction of $11,002,500.00. Following the completion of the sale, the director now directly owns 119,522 shares in the company, valued at $5,260,163.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Keros Therapeutics Trading Down 1.1 %
Shares of KROS stock opened at $45.54 on Friday. The company has a market cap of $1.64 billion, a PE ratio of -8.84 and a beta of 1.23. The company’s fifty day simple moving average is $46.84 and its 200-day simple moving average is $54.69. Keros Therapeutics, Inc. has a 52 week low of $27.02 and a 52 week high of $73.00.
Keros Therapeutics (NASDAQ:KROS – Get Free Report) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.02). The company had revenue of $0.04 million during the quarter. During the same period in the prior year, the company posted ($1.27) earnings per share. Equities research analysts expect that Keros Therapeutics, Inc. will post -4.8 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Check Out Our Latest Stock Analysis on KROS
Institutional Investors Weigh In On Keros Therapeutics
A number of large investors have recently modified their holdings of the stock. ADAR1 Capital Management LLC acquired a new position in Keros Therapeutics during the 4th quarter worth approximately $27,367,000. Redmile Group LLC purchased a new position in shares of Keros Therapeutics in the first quarter valued at $36,576,000. Darwin Global Management Ltd. grew its holdings in Keros Therapeutics by 35.4% during the 1st quarter. Darwin Global Management Ltd. now owns 1,435,950 shares of the company’s stock valued at $95,060,000 after purchasing an additional 375,523 shares in the last quarter. Franklin Resources Inc. increased its stake in Keros Therapeutics by 47.9% during the 4th quarter. Franklin Resources Inc. now owns 699,425 shares of the company’s stock worth $27,809,000 after buying an additional 226,674 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its holdings in Keros Therapeutics by 17.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,218,504 shares of the company’s stock worth $80,666,000 after buying an additional 176,803 shares in the last quarter. Institutional investors and hedge funds own 71.56% of the company’s stock.
About Keros Therapeutics
Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.
See Also
- Five stocks we like better than Keros Therapeutics
- Investing In Preferred Stock vs. Common Stock
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- NYSE Stocks Give Investors a Variety of Quality Options
- MarketBeat Week in Review – 8/12 – 8/16
- 3 Ways To Invest In Coffee, Other Than Drinking It
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for Keros Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keros Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.